Kidney cancer has never been particularly impressed by conventional chemotherapy. Fortunately, modern cancer treatment has learned a few new tricks. Immunotherapy can help the immune system recognize kidney cancer cells, remove the molecular “brakes” that prevent an attack, and sometimes produce responses that last for years.
Today, immune checkpoint inhibitors are central to the treatment of advanced renal cell carcinoma, the most common form of kidney cancer. They may be administered together, paired with targeted therapy, or used after surgery to lower the risk of recurrence. However, immunotherapy is not one magic medicine, and it does not work equally well for everyone. The best approach depends on the cancer subtype, stage, recurrence risk, previous treatments, overall health, and tolerance for possible side effects.
Medical note: This article provides general educational information and is not a substitute for individualized advice from an oncologist or other qualified healthcare professional.
What Is Immunotherapy for Kidney Cancer?
Immunotherapy is a form of systemic cancer treatment that helps the immune system identify or destroy malignant cells. Unlike surgery, which removes a tumor from a particular location, systemic treatment travels throughout the body. This makes it especially useful when kidney cancer has spread beyond the kidney or when microscopic cancer cells may remain after surgery.
The main immunotherapies used for renal cell carcinoma are immune checkpoint inhibitors. Checkpoints are proteins that normally prevent immune cells from becoming overactive and attacking healthy tissue. Kidney cancer cells can exploit these checkpoints like someone borrowing a security badge that definitely does not belong to them. Checkpoint inhibitors block that escape route and allow T cells to respond more aggressively.
Most modern regimens target one of three checkpoints:
- PD-1: Targeted by pembrolizumab and nivolumab.
- PD-L1: Targeted by avelumab.
- CTLA-4: Targeted by ipilimumab.
Older immune-based treatments, including high-dose interleukin-2 and interferon alfa, are now used far less often. They can benefit a small, carefully selected group of patients, but they generally cause more difficult side effects and have been replaced by checkpoint inhibitors in most situations.
When Is Kidney Cancer Immunotherapy Used?
After kidney cancer surgery
Surgery remains the main treatment for kidney cancer that is confined to the kidney or nearby tissues. Depending on the tumor, a surgeon may remove part of the kidney, the entire kidney, or visible metastatic deposits.
Some people with clear cell renal cell carcinoma have a substantial risk that the disease will return after surgery. Adjuvant immunotherapy is treatment given after apparently complete tumor removal to destroy microscopic cancer cells that scans cannot detect.
Pembrolizumab may be given for approximately one year after nephrectomy in eligible patients with intermediate-high or high-risk clear cell disease. In the KEYNOTE-564 trial, estimated overall survival at 48 months was 91.2% among participants receiving pembrolizumab and 86.0% among those receiving placebo. This was an important milestone because it demonstrated an overall survival benefit from adjuvant immunotherapy in this setting.
In June 2026, the FDA also approved belzutifan, a targeted HIF-2α inhibitor, in combination with pembrolizumab for certain adults with clear cell renal cell carcinoma at intermediate-high or high risk of recurrence after surgery. In the LITESPARK-022 trial, the combination reduced the risk of recurrence, metastasis, or death compared with pembrolizumab alone. Median disease-free survival had not yet been reached, and overall survival results were still immature when the approval was announced.
As initial treatment for advanced kidney cancer
When renal cell carcinoma cannot be removed surgically or has spread to distant organs, immunotherapy-based combinations are commonly used as first-line treatment. Standard options include two checkpoint inhibitors or a checkpoint inhibitor paired with a targeted drug that interferes with tumor blood-vessel growth.
These combinations have largely replaced older single-drug treatments because they can improve tumor response, delay progression, and, in several trials, help patients live longer.
After another treatment stops working
Nivolumab can be used by itself in some people whose advanced renal cell carcinoma progressed after anti-angiogenic therapy. In long-term results from the CheckMate 025 trial, median overall survival was 25.8 months with nivolumab and 19.7 months with everolimus. Five-year survival probabilities were 26% and 18%, respectively.
Treatment after progression now requires careful sequencing because many patients receive immunotherapy during their first line of treatment. Depending on what was previously used, later options may include cabozantinib, belzutifan, lenvatinib plus everolimus, tivozanib, another targeted drug, local treatment for limited metastases, or a clinical trial. Automatically repeating checkpoint therapy after progression has not consistently produced better results, so the plan should be individualized.
Types of Immunotherapy for Kidney Cancer
Nivolumab plus ipilimumab
Nivolumab blocks PD-1, while ipilimumab blocks CTLA-4. Using both drugs activates the immune response at two different control points. The combination is an established first-line option for advanced clear cell renal cell carcinoma, particularly for people with intermediate- or poor-risk disease.
In the original CheckMate 214 analysis, the objective response rate was approximately 42% with nivolumab plus ipilimumab and 27% with sunitinib. Complete responses occurred in about 9% of patients receiving immunotherapy.
The value of this regimen is especially visible over time. In a final analysis with a median follow-up of 9.3 years, the estimated 108-month overall survival rate was 31.4% with nivolumab plus ipilimumab and 19.5% with sunitinib in the overall trial population. Results do not guarantee that any individual patient will live for a particular length of time, but they demonstrate that durable survival is possible for a meaningful group of patients.
Ipilimumab is generally given for four doses, followed by nivolumab maintenance. This approach avoids the continuous use of a daily targeted therapy, but early immune-related side effects may be more frequent than with regimens containing a PD-1 inhibitor alone.
Pembrolizumab plus axitinib
Pembrolizumab is a PD-1 inhibitor, while axitinib is an oral tyrosine kinase inhibitor that blocks pathways involved in blood-vessel formation. The strategy attacks the disease from two directions: immunotherapy exposes cancer cells to immune attack, while targeted therapy interferes with the tumor’s blood supply.
In the KEYNOTE-426 trial, the objective response rate was 59.3% with pembrolizumab plus axitinib and 35.7% with sunitinib. Median progression-free survival in the initial report was 15.1 months versus 11.1 months. The combination also improved overall survival and remains a first-line option across International Metastatic RCC Database Consortium risk groups.
Axitinib can be paused or dose-adjusted relatively quickly, which may help clinicians investigate whether diarrhea, liver abnormalities, or another problem is being caused by the targeted drug or the immunotherapy.
Pembrolizumab plus lenvatinib
Lenvatinib is another oral tyrosine kinase inhibitor. When combined with pembrolizumab, it has produced one of the highest tumor response rates reported among first-line regimens for advanced renal cell carcinoma.
In the CLEAR trial, median progression-free survival was 23.9 months with lenvatinib plus pembrolizumab and 9.2 months with sunitinib. However, effectiveness came with considerable treatment burden: grade 3 or higher adverse events occurred in 82.4% of patients receiving the combination. Many side effects can be managed through dose interruptions, dose reductions, supportive medication, or treatment changes, but close monitoring is essential.
Nivolumab plus cabozantinib
Cabozantinib blocks several signaling pathways involved in tumor growth, blood-vessel formation, and cancer spread. The combination of nivolumab and cabozantinib is approved as an initial treatment for advanced renal cell carcinoma.
In the CheckMate 9ER trial, median progression-free survival was 16.6 months with nivolumab plus cabozantinib and 8.3 months with sunitinib. The combination also improved overall survival and the likelihood of tumor response.
Cabozantinib may be particularly attractive when physicians want a regimen with established activity in challenging disease locations, although treatment selection cannot be reduced to one feature. Blood pressure, liver function, gastrointestinal health, drug interactions, and the patient’s goals also matter.
Avelumab plus axitinib
Avelumab blocks PD-L1 and may be combined with axitinib. The JAVELIN Renal 101 trial demonstrated longer progression-free survival and a higher objective response rate than sunitinib. However, other combinations have produced clearer overall survival evidence and are frequently selected in contemporary practice. Avelumab plus axitinib remains an FDA-approved option that may be appropriate in selected circumstances.
High-dose interleukin-2
Interleukin-2 is a cytokine that stimulates immune cells. It can occasionally produce a deep and durable complete response, which is why it has not disappeared entirely into oncology’s attic. Unfortunately, high-dose IL-2 can cause severe low blood pressure, fluid accumulation, breathing problems, kidney dysfunction, irregular heart rhythms, and other dangerous complications.
It is generally reserved for a small number of medically fit patients treated at centers experienced with intensive monitoring. For most people, checkpoint inhibitors offer a better balance of effectiveness and practicality.
How Effective Is Immunotherapy for Kidney Cancer?
There is no single kidney cancer immunotherapy success rate. Efficacy depends on what is being measured, which regimen is used, the cancer subtype, the treatment setting, and the patient population studied.
Clinical trials commonly report:
- Objective response rate: The percentage of patients whose tumors shrink by a predefined amount.
- Complete response: The disappearance of all detectable cancer on imaging. It does not always mean the cancer can never return.
- Progression-free survival: The length of time before the disease worsens or the patient dies.
- Overall survival: The length of time patients remain alive after entering the study.
- Duration of response: How long tumor shrinkage continues.
A high response rate can be encouraging, but it is not the entire report card. A treatment may shrink tumors quickly yet cause substantial toxicity. Another may have a more modest response rate but create unusually durable responses. Long-term survival, symptom control, quality of life, and the ability to receive future treatments all matter.
Current evidence shows that immunotherapy-based combinations outperform older sunitinib treatment on important measures in many patients with advanced clear cell renal cell carcinoma. Nevertheless, some cancers never respond, and others initially shrink before developing resistance. Researchers are studying biomarkers, tumor genetics, circulating tumor DNA, immune-cell patterns, and other tools that may eventually predict the best regimen more precisely. At present, there is no universally reliable biomarker that neatly assigns every patient to one kidney cancer immunotherapy combination.
How Doctors Choose an Immunotherapy Regimen
The decision is based on more than a drug’s response-rate headline. An oncology team may consider:
- Clear cell versus non-clear cell histology
- IMDC favorable, intermediate, or poor-risk classification
- The location, volume, and speed of metastatic growth
- Whether rapid tumor shrinkage is urgently needed
- Previous surgery and systemic treatment
- Autoimmune disease or an organ transplant
- Heart, liver, kidney, thyroid, or bowel conditions
- Current medicines and possible drug interactions
- The patient’s daily routine and comfort with oral medication
- Personal priorities regarding side effects and quality of life
People with non-clear cell renal cell carcinoma may have fewer well-established immunotherapy options because many pivotal trials focused primarily on clear cell disease. Clinical trials can be particularly valuable for papillary, chromophobe, translocation-associated, medullary, collecting-duct, and other uncommon subtypes.
Side Effects of Kidney Cancer Immunotherapy
Common checkpoint inhibitor side effects
Fatigue is common and can range from “I need an earlier bedtime” to “my couch has become my legal residence.” Other possible effects include itching, rash, reduced appetite, nausea, diarrhea, constipation, cough, and joint discomfort.
Checkpoint inhibitors can also trigger immune-related adverse events. These occur when activated immune cells attack normal organs. Possible complications include:
- Colitis and severe diarrhea
- Hepatitis and elevated liver enzymes
- Pneumonitis, causing cough or shortness of breath
- Thyroid inflammation or reduced thyroid function
- Adrenal or pituitary dysfunction
- Type 1 diabetes
- Nephritis and worsening kidney function
- Serious skin, nerve, muscle, heart, or eye inflammation
These reactions may develop during treatment or after immunotherapy has ended. Early symptoms can appear mild, but prompt reporting matters because treatment with corticosteroids or other immune-suppressing medication can prevent serious complications. Patients should not wait until the next scheduled appointment to report persistent diarrhea, yellowing skin, chest pain, significant breathing trouble, marked weakness, confusion, severe headache, or major changes in urination.
Side effects from combination targeted therapy
When immunotherapy is paired with axitinib, lenvatinib, or cabozantinib, patients may also experience high blood pressure, mouth sores, diarrhea, loss of appetite, altered taste, hoarseness, hand-foot skin reactions, weight loss, thyroid changes, fatigue, and liver-test abnormalities.
Because the two drugs produce overlapping symptoms, identifying the cause can take detective work. The oncologist may temporarily hold the targeted drug, order blood tests, prescribe corticosteroids, reduce an oral dose, or pause both medicines. Dose adjustment does not automatically mean the treatment has failed; it often means the care team is trying to make an effective plan sustainable.
What to Expect During Treatment
Checkpoint inhibitors may be given through an intravenous infusion every two to six weeks, depending on the drug and schedule. Some formulations can be administered subcutaneously in eligible situations. Oral targeted medicines are usually taken once or twice daily.
Before and during treatment, patients generally have blood tests to evaluate blood counts, kidney function, liver enzymes, thyroid activity, glucose, electrolytes, and other markers. CT or MRI scans are performed periodically to determine whether tumors are shrinking, stable, or progressing.
Immunotherapy can occasionally produce unusual imaging patterns. A tumor may initially appear larger because immune cells have entered it, a phenomenon called pseudoprogression. True pseudoprogression is uncommon, however, so doctors interpret scans alongside symptoms, laboratory findings, growth patterns, and follow-up imaging rather than assuming every larger spot is an immune-system victory parade.
Questions to Ask the Oncology Team
- What subtype and risk category of kidney cancer do I have?
- What is the goal of this treatment?
- Why do you recommend this regimen over the alternatives?
- How likely is tumor shrinkage or long-term disease control?
- Which side effects require an urgent phone call?
- How will treatment affect my remaining kidney function?
- Can my oral drug be paused or reduced if side effects develop?
- Would a second opinion or clinical trial be useful?
- How long will treatment continue if it works?
- What treatment options remain if the cancer progresses?
The Real-World Experience of Kidney Cancer Immunotherapy
The practical experience of immunotherapy is often less dramatic than television medicine suggests. There may be no heroic countdown, no glowing machine, and no physician shouting, “Release the T cells!” A typical infusion visit may involve checking in, reviewing symptoms, having blood drawn, waiting for laboratory results, receiving medication, and heading home.
The quieter challenge is living between appointments. Patients may find themselves analyzing every cough, rash, stomach rumble, and tired afternoon. That vigilance is understandable because immune-related side effects can begin subtly. A symptom diary can help. Recording when a problem started, how often it occurs, and whether it interferes with eating, sleeping, walking, or working gives the oncology team more useful information than saying, “I felt weird sometime last week.”
Fatigue is one of the most common day-to-day complaints. It may fluctuate throughout a treatment cycle and may be influenced by anemia, thyroid dysfunction, poor sleep, reduced activity, emotional stress, or the cancer itself. Patients often benefit from pacing rather than trying to defeat fatigue through pure determination. Short walks, scheduled rest, consistent sleep, hydration, and accepting help with errands can be more productive than spending one energetic morning reorganizing the garage and the next two days regretting it.
Combination treatment can require additional routines. Someone taking a targeted drug may check blood pressure at home, use creams for hand-foot irritation, adjust meals around nausea or mouth sensitivity, and communicate regularly about diarrhea. Keeping an accurate medication list is essential because supplements, antibiotics, antifungal drugs, seizure medicines, and other products may interact with oral cancer therapy. “Natural” does not automatically mean “oncology approved.” Poison ivy is natural, too, and nobody invites it to dinner.
Scan days can be emotionally difficult. The time before results is sometimes called scanxiety, an unofficial word describing a very official feeling. Some people prefer to schedule scans early in the day, limit online portal checking, bring a support person, or arrange a calming activity afterward. Others want every measurement and graph immediately. There is no gold medal for coping in a particular style.
Responses also vary. One patient may see rapid tumor shrinkage; another may have stable disease that lasts for years. A third may need to switch treatment after early progression. Comparing experiences in support groups can provide encouragement, but another patient’s result cannot predict an individual outcome. Tumor biology, metastatic sites, previous treatment, overall health, and random biological variation all influence the course.
People who develop immune-related toxicity may feel conflicted when treatment is paused. A delay can feel like losing momentum, yet treating inflammation protects the lungs, liver, intestines, hormones, kidneys, and other organs. Some patients continue benefiting even after checkpoint therapy has stopped. Decisions about restarting treatment depend on the affected organ, severity of the reaction, response to corticosteroids, cancer status, and available alternatives.
Caregivers have their own workload. They may track appointments, notice subtle personality or energy changes, organize medications, communicate with clinicians, and provide emotional support while trying not to look worried. A written plan identifying whom to call during office hours, after hours, and in an emergency can reduce confusion. It is also sensible for caregivers to protect their own sleep, health appointments, and breaks. Exhaustion is not proof of devotion.
Financial and logistical concerns are part of the treatment experience as well. Insurance authorization, travel, infusion scheduling, missed work, parking, and prescription refills can become a second job that nobody applied for. Oncology social workers, patient navigators, pharmacists, nonprofit organizations, and manufacturer assistance programs may help address transportation, copays, disability paperwork, or medication access.
The most useful mindset is neither blind optimism nor constant catastrophe planning. Immunotherapy has created meaningful long-term survival possibilities that were uncommon in earlier eras of metastatic kidney cancer. It also carries uncertainty and potentially serious toxicity. Staying informed, reporting symptoms promptly, and maintaining honest communication with the care team can make treatment safer and more manageable.
Conclusion
Immunotherapy has transformed kidney cancer treatment. Checkpoint inhibitors such as pembrolizumab, nivolumab, ipilimumab, and avelumab can be used after surgery, as initial therapy for advanced disease, or in selected later-line situations. They may be administered together or combined with targeted treatments such as axitinib, lenvatinib, cabozantinib, or belzutifan.
Clinical trials show that several immunotherapy-based regimens improve response rates, progression-free survival, or overall survival compared with older treatments. Some patients achieve durable responses lasting many years. Others receive little benefit, and serious immune-related side effects remain possible. Choosing among available options requires a personalized discussion about tumor subtype, recurrence risk, previous therapy, health conditions, quality-of-life priorities, and clinical trial opportunities.
